Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Exclusion Criteria

• •Each subject must not have:
• •1. History of any meningococcal vaccine administration other than the single vaccination given 4 to 6 years before OR History of any meningococcal vaccine administration.
• •2. Current or previous, confirmed or suspected disease caused by N. meningitidis.
• •3. Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days prior to study vaccination.
• •4. Progressive, unstable or uncontrolled clinical conditions.
• •5. Hypersensitivity, including allergy, to any component of vaccines, medicinal products or medical equipment whose use is foreseen in this study.
• •6. Clinical conditions representing a contraindication to intramuscular vaccination (IM) and blood draws.
• •7. Abnormal function of the immune system resulting from:
• •1. Clinical conditions.
• •2. Systemic administration of corticosteroids for more than 14 consecutive days within 90 days prior to study vaccination.
• •3. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination.
• •8. Received immunoglobulins or any blood products within 180 days prior to informed consent.
• •9. Received systemic antibiotic treatment within 3 days prior to study vaccination or blood draw.
• •10. Received an investigational or non-registered medicinal product within 30 days prior to study vaccination.
• •11. Study personnel as an immediate family or household member.
• •12. Individuals who have received any other vaccines within 7 days or 14 days prior to vaccination in this study or who are planning to receive any vaccine within 28 days from the study vaccination.
• •13. Individuals who have experienced a moderate or severe acute infection and/or fever defined as a temperature ≥38°C (100.4°F) within 3 days prior to study vaccination.
• •14. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.